Error message

The page you requested does not exist. For your convenience, a search was performed using the query cbssm med umich edu people andrew shuman md.

Page not found

You are here

Wed, February 15, 2017

According to a study by Reshma Jagsi and colleagues, doctors often fail to recommend genetic testing for breast-cancer patients, even those who are at high risk for mutations linked to ovarian and other cancers. They surveyed 2,529 breast-cancer patients and found that although two-thirds of the women reported wanting genetic testing, less than a third actually got it. About 8 in 10 women at highest risk for BRCA mutations — because of family history or ancestry — said they had wanted testing, but only a little more than half received it.

"Concussion" Film Screening & Moderated Discussion

Thu, March 30, 2017, 7:00pm
Location: 
Forum Hall, Palmer Commons

"Concussion" Film Screening & Moderated Discussion

Free Admission

Moderator:    Raymond De Vries, PhD

Panelists:    

  • Ellen Arruda, PhD, Professor, Mechanical Engineering
  • Karen Kelly-Blake, PhD, Assistant Professor, Center for Ethics and Humanities in the Life Sciences, MSU
  • Matthew Lorincz, MD, PhD, Associate Professor, Neurology, Co-Director, Michigan NeuroSport

Refreshments provided.

Join us for a free screening of the award-winning film, Concussion. Watch the true story of Dr. Bennet Omalu, renowned forensic pathologist who discovered chronic traumatic encephalopathy (CTE), acclaimed as, "a gripping medical mystery and a dazzling portrait of the young scientist no one wanted to listen to." 

The film will be followed by a panel discussion related to key bioethical and scientific issues brought up by the film, as well as current research into brain injury and brain injury prevention.

Jodyn Platt, MPH, PhD, Assistant Professor of Learning Health Sciences, has been named a University of Chicago MacLean Fellow.

As part of the one year Cancer Genomics and Ethics Big Data Science Fellowship she will receive clinical training in the Medical Ethics Summer Intensive Program and conduct a research project with Olufunmilayo Olopade, MD, FACP, Director of the Center for Clinical Cancer Genetics at University of Chicago Medicine.

Platt explains how her work as a fellow will begin: "I would like to systematically observe and interview individuals involved in shaping how data evolves and moves from the patient encounter to the big data enterprise and back to clinical care." Looking forward to expanding her network over the course of the year, she plans "to engage in, and lead, interdisciplinary scholarship that will ensure the revolution in healthcare delivery brought on by big data and cancer genomics is an ethical one." 

Platt is also the organizer of the upcoming ELSI-LHS symposium on November 15th at U-M which explores the “Ethical, Legal and Social Implications of Learning Health Systems”.

Funded by the Department of Veterans Affairs

Funding Year: 2011

A current priority for VA research is "Healthcare Informatics to Improve Veteran Care Healthcare." This priority area recognizes the critical importance of developing effective technological tools for Veterans to improve their understanding of and capacity to be actively involved in shared decision making about key health issues. Making The Choice - VA will develop new materials specifically for VA patients who have prostate cancer. The tool will help in shared and informed decision-making related to prostate cancer treatment options and outcomes. 

Aim 1. Develop a web-based platform that will support informed shared decision making for patients. The focus will be prostate cancer treatment options.

Aim 2. Use values clarification method, conjoint analysis, in this first iteration of the platform.

Angela Fagerlin (PI)

Center for Health Communications Research (CHCR)

 

Funded by Department of Veterans Affairs

Funding Years: 2009-2012

Because CRC-predictive genetic tests offer the potential to optimize CRC screening efforts, improving the communication and use of such tests by the millions of veterans who are screened for CRC each year could result in both improved cancer surveillance and more efficient (and potentially reduced) VA resource utilization. Our study will provide empirical data about practical risk communication methods that can be used in the future by VA clinicians to present genetic tests to veterans and about patient-level barriers which will inhibit acceptance of genetic tests that predict colorectal cancer risk within the VA patient population. By evaluating alternate methods of communicating genetic test results before such tests actually become available, we hope to identify optimal approaches that can be integrated into VA genomics initiatives from the very start.

Angela Fagerlin (PI)

Funded by the National Institutes of Health

Funding years: 2009-2014

The Specific Aims of this study are (1) to examine patterns and correlates of quality of adjuvant chemotherapy in a population-based sample of women, (2) to examine patterns and correlates of quality of breast cancer hormonal therapy in a population-based sample of women with breast cancer, and (3) to estimate the frequency of classification error in key pathologic variables-ER and HER2 status-in a population-based sample of women with breast cancer and explore the impact of such error on receipt of optimal adjuvant systemic therapy. We propose to investigate these factors through patient interview, medical record review, and repeat assessment of pathologic variables on primary tumor specimens. The results of this study will be used to advance methods in oncology outcomes research and to inform policy and practice interventions to improve the quality of breast cancer care in the United States. For more information, visit NIH Reporter.

PI(s): Jennifer Griggs, Steven Katz

Co-I: Sarah Hawley

Erica Sutton, PhD

Alumni

Dr. Erica Sutton was a CBSSM Postdoctoral Research Fellow, 2013-2015. She is an interdisciplinary social scientist engaged in social and behavioral science research that explores the health care experiences of individuals living with rare genetic conditions; the manner in which biotechnologies shape personal experience and social life; and the ethical implications of these technologies for individuals, public health, social policy, health care institutions, and communities.

Last Name: 
Sutton

Aisha Langford PhD, MPH

Alumni

Dr. Aisha Langford was a VA and CBSSM Postdoctoral Research Fellow, 2013-2015. She received her PhD from the department of Health Behavior and Health Education at the University of Michigan School of Public Health in Ann Arbor. From 2007 -2013, she directed the University of Michigan Comprehensive Cancer Center’s Community Outreach Program. Her research interests include chronic disease prevention and control, health communications, medical decision making, and clinical trial participation. Aisha is from the San Francisco Bay Area and earned her BA from the University of Virginia.

Last Name: 
Langford

Funded by Robert Wood Johnson Foundation

Funding Years: 2013 - 2014.

Patients and the public are being inundated with a flood of health data and being asked to take a greater role in applying this data to make medical decisions regarding their own health. While general guidelines exist for "best practices" in medical risk communication, this work has not always considered the specific communication goals of the risk message or the specific information or practical needs of the patient. The Communicating Health and Risk Messages (CHARM) project will address the gap in our current knowledge by informing the design of health risk data visualizations across the full spectrum of risk communication goals.

PI(s): Victor Strecher

Co-I(s): Lawrence An, Angela Fagerlin, Kenneth Resnicow, Brian Zikmund-Fisher

Funded by Department of Health and Human Services - National Institutes of Health Subcontracts

Funding Years: 2014 - 2018.

This five-year prevention trial proposes to test an anti-amyloid drug in cognitively normal older volunteers who are at increased risk of developing late-onset Alzheimer’s because they inherited two copies of the APOE4 allele, the best known genetic risk for late-onset disease. The treatment, which has not yet been selected, will be tested in this randomized, controlled clinical trial at multiple sites. Participants will be assessed through cognitive tests, brain imaging and cerebrospinal fluid measurements to evaluate whether the drug impacts amyloid, other biological measurements and the memory and thinking problems related to the disease. The study will test the role of amyloid in the development of Alzheimer’s and will, through imaging and biomarker techniques, help identify faster ways to evaluate other promising prevention therapies in the future. It is anticipated that the study will also be supported with private funding.

PI(s): J. Scott Roberts

Pages